Ph II Study of Wkly Topotecan + Bevacizumab in Plat. Resistant/Recurrent Gyn Cancers
Status:
Completed
Trial end date:
2011-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the clinical safety and toxicity of intravenous
bevacizumab (Days 1 and 15 of a 28 day cycle) in combination with weekly topotecan (Days 1,
8, 15 of a 28 day cycle) in patients with platinum resistant recurrent ovarian, fallopian
tube and primary peritoneal cancer.